About Shionogi

  1. TOP > 
  2. About Shionogi > 
  3. 2019 Press Release

2019 Press Release

  • Jan
  • Feb
  • Mar
  • Apr
  • May
  • Jun
  • Jul
  • Aug
  • Sep
  • Oct
  • Nov
  • Dec


Shionogi Announces Commencement of Tender Offer for Certificates of Shares, Etc. in UMN Pharma Inc. (Securities Code: 8840)
Launch of “BNP Control Shionogi”, a Common Reference Standard Material for BNP Test
Shionogi Provides Update on the Japanese Association for Infectious Diseases Statement and the Revised Guidelines of the Japanese Pediatric Society for the Treatment of Influenza
FDA Approves XOFLUZA™ (Baloxavir Marboxil) for the Treatment of Acute Uncomplicated Influenza for People at High Risk of Developing Influenza-Related Complications
Shionogi, Janssen, and Alzheimer’s Drug Discovery Foundation Announced a “Clinical Sample Access Agreement” at WDC 2019 Summit
U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections
Shionogi Filed for the Supplemental New Drug Application of XOFLUZA® in Japan for the Post-Exposure Prophylaxis of Influenza Virus Infection
Shionogi Received “2019 Award for Excellence in Corporate Disclosure” for Three Consecutive Year from the Securities Analysts Association of Japan (SAAJ)
Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
M3 and Shionogi Joint Venture for Disease Solution - Establishment of Stream-I, Inc. -
Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens APEKS-NP trial met primary endpoint of non-inferiority of cefiderocol compared to meropenem
Congress Presentation on Clinical Study of S-600918, a Drug Candidate for the Treatment of Refractory/Unexplained Chronic Cough - Favorable Results of Phase II Study Presented at the European Respiratory Society International Congress (ERS 2019)

page top

page top